#USA #New York #Class Action #Novo Nordisk #A/S

Warning to Shareholders of Novo Nordisk A/S

In a pressing announcement, The Gross Law Firm is reaching out to the shareholders of Novo Nordisk A/S (NYSE: NVO), inviting those who purchased shares during a specified class period to consider joining a class action lawsuit. This notice comes as many investors have faced substantial losses due to alleged misleading statements by the company's management.

Background of the Case

The class period for this action spans from May 7, 2025, to July 28, 2025. During this time, shareholders reportedly relied on the positive statements made by Novo Nordisk about its market potential and growth. However, the reality appears to be starkly different. According to the allegations filed in the complaint, Novo’s leadership allegedly provided overly optimistic projections while concealing crucial negative information regarding the company's actual performance and market challenges.

Allegations and Decline in Stock Value

The lawsuit claims that the company misrepresented its ability to tap into the compounded GLP-1 market, which has remained a significant area of focus for Novo. It further accuses the defendants of exaggerating the prospects for their popular diabetes treatments, namely Wegovy and Ozempic. Such misleading statements contributed to an inflated stock price that ultimately came crashing down.

On July 29, 2025, Novo Nordisk shocked investors by announcing a downgrading of its sales and profit forecast for the remainder of the fiscal year. This announcement highlighted a combination of lower growth expectations and intense competition, leading to a dramatic stock market reaction. From a closing price of $69.00 on July 28, the share value plummeted nearly 21.83%, closing at $53.94 the following day.

Call to Action for Shareholders

Given the potential for recovery, shareholders who purchased NVO shares during the defined period are strongly encouraged to reach out to The Gross Law Firm. Importantly, registering as a lead plaintiff is not mandatory to seek potential recovery in this case.

To ensure that your rights are protected and to be kept informed about this case's progression, affected shareholders should register their information promptly. The window for registering as a lead plaintiff officially closes on September 30, 2025. Interested individuals can find the registration link on the firm’s website.

The Firm's Commitment

The Gross Law Firm is a nationally recognized class action law firm dedicated to safeguarding the rights of deceived investors. They advocate for fair corporate practices and installation of accountability in large corporations. With a strong commitment to transparency and reform in business practices, the firm seeks restitution for individuals impacted by unethical corporate behavior.

Contact Information

For more details about this class action lawsuit or to register, shareholders can get in touch with The Gross Law Firm:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

The time-sensitive nature of this lawsuit means that affected shareholders should act quickly. The Gross Law Firm is here to guide concerned investors through the complexities of class action participation.

Conclusion

As the February 2025 deadline for filing approaches, affected shareholders must not delay in joining this class action. The allegations against Novo Nordisk reveal a troubling narrative that could resonate with many investors facing losses. Reaching out for support could make a significant difference in pursuing recovery.